aluates Reports

$ 0.0

Automative

Glucagon Like Peptide-1 (GLP-1) Agonists- Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031

Published Date: August 2025

Report Code: QYRE-Auto-34Y65

Global Glucagon Like Peptide 1 GLP 1 Agonists Market Insights and Forecast to 2028

BUY CHAPTERS

Glucagon Like Peptide-1 (GLP-1) Agonists- Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031

Code: QYRE-Auto-34Y65

Report

August 2025

Pages:92

QYResearch

Buy Now with 15% Discount

DESCRIPTION

TABLE OF CONTENT

TABLES & FIGURES

FEATURED COMPANIES

Astrazeneca plc

GSK

Sanofi

Novo Nordisk

Eli Lilly

Hanson

Shanghai Benemae

Glucagon Like Peptide-1 (GLP-1) Agonists- Market Size

The global market for Glucagon Like Peptide-1 (GLP-1) Agonists was estimated to be worth US$ 108120 million in 2024 and is forecast to a readjusted size of US$ 490060 million by 2031 with a CAGR of 24.5% during the forecast period 2025-2031.

Glucagon Like Peptide-1 (GLP-1) Agonists- Market

Glucagon like peptide-1 (GLP-1) agonists is the agonists of the GLP-1 receptor. This class of drugs is used for the treatment of type 2 diabetes. One of their advantages is over older insulin secretagogues, such as sulfonylureas or meglitinides, and they have a lower risk of causing hypoglycemia.

The Glucagon-Like Peptide-1 (GLP-1) Agonists market, which focuses on drugs used for treating type 2 diabetes and obesity, is influenced by several important drivers and challenges:

Market Drivers:

Rising Prevalence of Diabetes and Obesity: The increasing global incidence of type 2 diabetes and obesity is driving demand for GLP-1 agonists, as they are effective in controlling blood sugar levels and aiding weight loss.

Shift Towards Injectable and Oral Therapies: Growing patient acceptance of injectable therapies (such as GLP-1 agonists) and the introduction of oral GLP-1 agonists (like semaglutide) are expanding the market.

Favorable Clinical Outcomes: GLP-1 agonists have shown promising results in managing glycemic control, cardiovascular risk reduction, and weight management, making them a preferred option among healthcare providers.

Increased Awareness and Screening: Governments and healthcare organizations are running campaigns to increase awareness about diabetes management, which is boosting demand for GLP-1 agonists.

Product Innovations: Continuous innovations and the development of longer-acting GLP-1 formulations with fewer side effects are improving patient compliance and market growth.

Market Challenges:

High Treatment Costs: GLP-1 agonists tend to be expensive, which can limit access, particularly in low-income or underdeveloped healthcare systems.

Side Effects and Contraindications: Some patients experience gastrointestinal side effects (like nausea and vomiting) with GLP-1 agonists, potentially limiting widespread use.

Competition from Other Diabetes Treatments: While GLP-1 agonists are effective, there is stiff competition from other diabetes drugs, including DPP-4 inhibitors, SGLT2 inhibitors, and insulin therapies.

Patient Adherence: Although the drug is effective, some patients may struggle with the required injections (for injectable GLP-1 agonists) or discontinuation due to side effects, leading to adherence challenges.

Regulatory and Reimbursement Barriers: The approval process for new GLP-1 agonist formulations, coupled with inconsistent reimbursement policies, can hinder the availability of these drugs in certain markets.

Novo Nordisk, AstraZeneca, Eli Lilly, GSK and Sanofi are the leader of the industry. Novo Nordisk is the top one of this industry. United States is the largest consumer of Glucagon like peptide-1 (GLP-1) agonists The second place is Europe.

This report aims to provide a comprehensive presentation of the global market for Glucagon Like Peptide-1 (GLP-1) Agonists, focusing on the total sales volume, sales revenue, price, key companies market share and ranking, together with an analysis of Glucagon Like Peptide-1 (GLP-1) Agonists by region & country, by Type, and by Application.

The Glucagon Like Peptide-1 (GLP-1) Agonists market size, estimations, and forecasts are provided in terms of sales volume (K Units) and sales revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Glucagon Like Peptide-1 (GLP-1) Agonists.

Market Segmentation

Scope of Glucagon Like Peptide-1 (GLP-1) Agonists- Market Report

Report Metric	Details
Report Name	Glucagon Like Peptide-1 (GLP-1) Agonists- Market
Forecasted market size in 2031	US$ 490060 million
CAGR	24.5%
Forecasted years	2025 - 2031
Segment by Type	Dulaglutide Exenatide Liraglutide Benaglutide Other
Segment by Application	Diabetes Obesity
By Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Rest of Europe Nordic Countries Asia-Pacific (China, Japan, South Korea) Southeast Asia (India, Australia) Rest of Asia Latin America (Mexico, Brazil) Rest of Latin America Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company	Novo Nordisk, Eli Lilly, AstraZeneca, Sanofi, GSK, Hanson, Shanghai Benemae
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size (value, volume and price). This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Glucagon Like Peptide-1 (GLP-1) Agonists manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Sales, revenue of Glucagon Like Peptide-1 (GLP-1) Agonists in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Sales, revenue of Glucagon Like Peptide-1 (GLP-1) Agonists in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.

FAQ for this report

What is the Glucagon Like Peptide-1 (GLP-1) Agonists- Market size in 2031?

Ans: The Glucagon Like Peptide-1 (GLP-1) Agonists- Market size in 2031 will be US$ 490060 million.

Who are the main players in the Glucagon Like Peptide-1 (GLP-1) Agonists- Market report?

Ans: The main players in the Glucagon Like Peptide-1 (GLP-1) Agonists- Market are Novo Nordisk, Eli Lilly, AstraZeneca, Sanofi, GSK, Hanson, Shanghai Benemae

What are the Application segmentation covered in the Glucagon Like Peptide-1 (GLP-1) Agonists- Market report?

Ans: The Applications covered in the Glucagon Like Peptide-1 (GLP-1) Agonists- Market report are Diabetes, Obesity

What are the Type segmentation covered in the Glucagon Like Peptide-1 (GLP-1) Agonists- Market report?

Ans: The Types covered in the Glucagon Like Peptide-1 (GLP-1) Agonists- Market report are Dulaglutide, Exenatide, Liraglutide, Benaglutide, Other

1 Market Overview

1.1 Glucagon Like Peptide-1 (GLP-1) Agonists Product Introduction

1.2 Global Glucagon Like Peptide-1 (GLP-1) Agonists Market Size Forecast

1.2.1 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value (2020-2031)

1.2.2 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Volume (2020-2031)

1.2.3 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Price (2020-2031)

1.3 Glucagon Like Peptide-1 (GLP-1) Agonists Market Trends & Drivers

1.3.1 Glucagon Like Peptide-1 (GLP-1) Agonists Industry Trends

1.3.2 Glucagon Like Peptide-1 (GLP-1) Agonists Market Drivers & Opportunity

1.3.3 Glucagon Like Peptide-1 (GLP-1) Agonists Market Challenges

1.3.4 Glucagon Like Peptide-1 (GLP-1) Agonists Market Restraints

1.4 Assumptions and Limitations

1.5 Study Objectives

1.6 Years Considered

2 Competitive Analysis by Company

2.1 Global Glucagon Like Peptide-1 (GLP-1) Agonists Players Revenue Ranking (2024)

2.2 Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Company (2020-2025)

2.3 Global Glucagon Like Peptide-1 (GLP-1) Agonists Players Sales Volume Ranking (2024)

2.4 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Volume by Company Players (2020-2025)

2.5 Global Glucagon Like Peptide-1 (GLP-1) Agonists Average Price by Company (2020-2025)

2.6 Key Manufacturers Glucagon Like Peptide-1 (GLP-1) Agonists Manufacturing Base and Headquarters

2.7 Key Manufacturers Glucagon Like Peptide-1 (GLP-1) Agonists Product Offered

2.8 Key Manufacturers Time to Begin Mass Production of Glucagon Like Peptide-1 (GLP-1) Agonists

2.9 Glucagon Like Peptide-1 (GLP-1) Agonists Market Competitive Analysis

2.9.1 Glucagon Like Peptide-1 (GLP-1) Agonists Market Concentration Rate (2020-2025)

2.9.2 Global 5 and 10 Largest Manufacturers by Glucagon Like Peptide-1 (GLP-1) Agonists Revenue in 2024

2.9.3 Global Top Manufacturers by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Glucagon Like Peptide-1 (GLP-1) Agonists as of 2024)

2.10 Mergers & Acquisitions, Expansion

3 Segmentation by Type

3.1 Introduction by Type

3.1.1 Dulaglutide

3.1.2 Exenatide

3.1.3 Liraglutide

3.1.4 Benaglutide

3.1.5 Other

3.2 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value by Type

3.2.1 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value by Type (2020 VS 2024 VS 2031)

3.2.2 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value, by Type (2020-2031)

3.2.3 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value, by Type (%) (2020-2031)

3.3 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Volume by Type

3.3.1 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Volume by Type (2020 VS 2024 VS 2031)

3.3.2 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Volume, by Type (2020-2031)

3.3.3 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Volume, by Type (%) (2020-2031)

3.4 Global Glucagon Like Peptide-1 (GLP-1) Agonists Average Price by Type (2020-2031)

4 Segmentation by Application

4.1 Introduction by Application

4.1.1 Diabetes

4.1.2 Obesity

4.2 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value by Application

4.2.1 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value by Application (2020 VS 2024 VS 2031)

4.2.2 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value, by Application (2020-2031)

4.2.3 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value, by Application (%) (2020-2031)

4.3 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Volume by Application

4.3.1 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Volume by Application (2020 VS 2024 VS 2031)

4.3.2 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Volume, by Application (2020-2031)

4.3.3 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Volume, by Application (%) (2020-2031)

4.4 Global Glucagon Like Peptide-1 (GLP-1) Agonists Average Price by Application (2020-2031)

5 Segmentation by Region

5.1 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value by Region

5.1.1 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value by Region: 2020 VS 2024 VS 2031

5.1.2 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value by Region (2020-2025)

5.1.3 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value by Region (2026-2031)

5.1.4 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value by Region (%), (2020-2031)

5.2 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Volume by Region

5.2.1 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Volume by Region: 2020 VS 2024 VS 2031

5.2.2 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Volume by Region (2020-2025)

5.2.3 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Volume by Region (2026-2031)

5.2.4 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Volume by Region (%), (2020-2031)

5.3 Global Glucagon Like Peptide-1 (GLP-1) Agonists Average Price by Region (2020-2031)

5.4 North America

5.4.1 North America Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value, 2020-2031

5.4.2 North America Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value by Country (%), 2024 VS 2031

5.5 Europe

5.5.1 Europe Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value, 2020-2031

5.5.2 Europe Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value by Country (%), 2024 VS 2031

5.6 Asia Pacific

5.6.1 Asia Pacific Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value, 2020-2031

5.6.2 Asia Pacific Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value by Region (%), 2024 VS 2031

5.7 South America

5.7.1 South America Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value, 2020-2031

5.7.2 South America Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value by Country (%), 2024 VS 2031

5.8 Middle East & Africa

5.8.1 Middle East & Africa Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value, 2020-2031

5.8.2 Middle East & Africa Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value by Country (%), 2024 VS 2031

6 Segmentation by Key Countries/Regions

6.1 Key Countries/Regions Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Growth Trends, 2020 VS 2024 VS 2031

6.2 Key Countries/Regions Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value

6.2.1 Key Countries/Regions Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value, 2020-2031

6.2.2 Key Countries/Regions Glucagon Like Peptide-1 (GLP-1) Agonists Sales Volume, 2020-2031

6.3 United States

6.3.1 United States Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value, 2020-2031

6.3.2 United States Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value by Type (%), 2024 VS 2031

6.3.3 United States Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value by Application, 2024 VS 2031

6.4 Europe

6.4.1 Europe Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value, 2020-2031

6.4.2 Europe Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value by Type (%), 2024 VS 2031

6.4.3 Europe Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value by Application, 2024 VS 2031

6.5 China

6.5.1 China Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value, 2020-2031

6.5.2 China Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value by Type (%), 2024 VS 2031

6.5.3 China Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value by Application, 2024 VS 2031

6.6 Japan

6.6.1 Japan Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value, 2020-2031

6.6.2 Japan Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value by Type (%), 2024 VS 2031

6.6.3 Japan Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value by Application, 2024 VS 2031

6.7 South Korea

6.7.1 South Korea Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value, 2020-2031

6.7.2 South Korea Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value by Type (%), 2024 VS 2031

6.7.3 South Korea Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value by Application, 2024 VS 2031

6.8 Southeast Asia

6.8.1 Southeast Asia Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value, 2020-2031

6.8.2 Southeast Asia Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value by Type (%), 2024 VS 2031

6.8.3 Southeast Asia Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value by Application, 2024 VS 2031

6.9 India

6.9.1 India Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value, 2020-2031

6.9.2 India Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value by Type (%), 2024 VS 2031

6.9.3 India Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value by Application, 2024 VS 2031

7 Company Profiles

7.1 Novo Nordisk

7.1.1 Novo Nordisk Company Information

7.1.2 Novo Nordisk Introduction and Business Overview

7.1.3 Novo Nordisk Glucagon Like Peptide-1 (GLP-1) Agonists Sales, Revenue, Price and Gross Margin (2020-2025)

7.1.4 Novo Nordisk Glucagon Like Peptide-1 (GLP-1) Agonists Product Offerings

7.1.5 Novo Nordisk Recent Development

7.2 Eli Lilly

7.2.1 Eli Lilly Company Information

7.2.2 Eli Lilly Introduction and Business Overview

7.2.3 Eli Lilly Glucagon Like Peptide-1 (GLP-1) Agonists Sales, Revenue, Price and Gross Margin (2020-2025)

7.2.4 Eli Lilly Glucagon Like Peptide-1 (GLP-1) Agonists Product Offerings

7.2.5 Eli Lilly Recent Development

7.3 AstraZeneca

7.3.1 AstraZeneca Company Information

7.3.2 AstraZeneca Introduction and Business Overview

7.3.3 AstraZeneca Glucagon Like Peptide-1 (GLP-1) Agonists Sales, Revenue, Price and Gross Margin (2020-2025)

7.3.4 AstraZeneca Glucagon Like Peptide-1 (GLP-1) Agonists Product Offerings

7.3.5 AstraZeneca Recent Development

7.4 Sanofi

7.4.1 Sanofi Company Information

7.4.2 Sanofi Introduction and Business Overview

7.4.3 Sanofi Glucagon Like Peptide-1 (GLP-1) Agonists Sales, Revenue, Price and Gross Margin (2020-2025)

7.4.4 Sanofi Glucagon Like Peptide-1 (GLP-1) Agonists Product Offerings

7.4.5 Sanofi Recent Development

7.5 GSK

7.5.1 GSK Company Information

7.5.2 GSK Introduction and Business Overview

7.5.3 GSK Glucagon Like Peptide-1 (GLP-1) Agonists Sales, Revenue, Price and Gross Margin (2020-2025)

7.5.4 GSK Glucagon Like Peptide-1 (GLP-1) Agonists Product Offerings

7.5.5 GSK Recent Development

7.6 Hanson

7.6.1 Hanson Company Information

7.6.2 Hanson Introduction and Business Overview

7.6.3 Hanson Glucagon Like Peptide-1 (GLP-1) Agonists Sales, Revenue, Price and Gross Margin (2020-2025)

7.6.4 Hanson Glucagon Like Peptide-1 (GLP-1) Agonists Product Offerings

7.6.5 Hanson Recent Development

7.7 Shanghai Benemae

7.7.1 Shanghai Benemae Company Information

7.7.2 Shanghai Benemae Introduction and Business Overview

7.7.3 Shanghai Benemae Glucagon Like Peptide-1 (GLP-1) Agonists Sales, Revenue, Price and Gross Margin (2020-2025)

7.7.4 Shanghai Benemae Glucagon Like Peptide-1 (GLP-1) Agonists Product Offerings

7.7.5 Shanghai Benemae Recent Development

8 Industry Chain Analysis

8.1 Glucagon Like Peptide-1 (GLP-1) Agonists Industrial Chain

8.2 Glucagon Like Peptide-1 (GLP-1) Agonists Upstream Analysis

8.2.1 Key Raw Materials

8.2.2 Raw Materials Key Suppliers

8.2.3 Manufacturing Cost Structure

8.3 Midstream Analysis

8.4 Downstream Analysis (Customers Analysis)

8.5 Sales Model and Sales Channels

8.5.1 Glucagon Like Peptide-1 (GLP-1) Agonists Sales Model

8.5.2 Sales Channel

8.5.3 Glucagon Like Peptide-1 (GLP-1) Agonists Distributors

9 Research Findings and Conclusion

10 Appendix

10.1 Research Methodology

10.1.1 Methodology/Research Approach

10.1.1.1 Research Programs/Design

10.1.1.2 Market Size Estimation

10.1.1.3 Market Breakdown and Data Triangulation

10.1.2 Data Source

10.1.2.1 Secondary Sources

10.1.2.2 Primary Sources

10.2 Author Details

10.3 Disclaimer

FEATURED COMPANIES

Astrazeneca plc

GSK

Sanofi

Novo Nordisk

Eli Lilly

Hanson

Shanghai Benemae

List of Tables

Table 1. Glucagon Like Peptide-1 (GLP-1) Agonists Market Trends

Table 2. Glucagon Like Peptide-1 (GLP-1) Agonists Market Drivers & Opportunity

Table 3. Glucagon Like Peptide-1 (GLP-1) Agonists Market Challenges

Table 4. Glucagon Like Peptide-1 (GLP-1) Agonists Market Restraints

Table 5. Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Company (2020-2025) & (US$ Million)

Table 6. Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Market Share by Company (2020-2025)

Table 7. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Volume by Company (2020-2025) & (K Units)

Table 8. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Volume Market Share by Company (2020-2025)

Table 9. Global Market Glucagon Like Peptide-1 (GLP-1) Agonists Price by Company (2020-2025) & (USD/Unit)

Table 10. Key Manufacturers Glucagon Like Peptide-1 (GLP-1) Agonists Manufacturing Base and Headquarters

Table 11. Key Manufacturers Glucagon Like Peptide-1 (GLP-1) Agonists Product Type

Table 12. Key Manufacturers Time to Begin Mass Production of Glucagon Like Peptide-1 (GLP-1) Agonists

Table 13. Global Glucagon Like Peptide-1 (GLP-1) Agonists Manufacturers Market Concentration Ratio (CR5 and HHI)

Table 14. Global Top Manufacturers Market Share by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Glucagon Like Peptide-1 (GLP-1) Agonists as of 2024)

Table 15. Mergers & Acquisitions, Expansion Plans

Table 16. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value by Type: 2020 VS 2024 VS 2031 (US$ Million)

Table 17. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value by Type (2020-2025) & (US$ Million)

Table 18. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value by Type (2026-2031) & (US$ Million)

Table 19. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Market Share in Value by Type (2020-2025)

Table 20. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Market Share in Value by Type (2026-2031)

Table 21. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Volume by Type: 2020 VS 2024 VS 2031 (K Units)

Table 22. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Volume by Type (2020-2025) & (K Units)

Table 23. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Volume by Type (2026-2031) & (K Units)

Table 24. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Market Share in Volume by Type (2020-2025)

Table 25. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Market Share in Volume by Type (2026-2031)

Table 26. Global Glucagon Like Peptide-1 (GLP-1) Agonists Price by Type (2020-2025) & (USD/Unit)

Table 27. Global Glucagon Like Peptide-1 (GLP-1) Agonists Price by Type (2026-2031) & (USD/Unit)

Table 28. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value by Application: 2020 VS 2024 VS 2031 (US$ Million)

Table 29. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value by Application (2020-2025) & (US$ Million)

Table 30. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value by Application (2026-2031) & (US$ Million)

Table 31. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Market Share in Value by Application (2020-2025)

Table 32. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Market Share in Value by Application (2026-2031)

Table 33. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Volume by Application: 2020 VS 2024 VS 2031 (K Units)

Table 34. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Volume by Application (2020-2025) & (K Units)

Table 35. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Volume by Application (2026-2031) & (K Units)

Table 36. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Market Share in Volume by Application (2020-2025)

Table 37. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Market Share in Volume by Application (2026-2031)

Table 38. Global Glucagon Like Peptide-1 (GLP-1) Agonists Price by Application (2020-2025) & (USD/Unit)

Table 39. Global Glucagon Like Peptide-1 (GLP-1) Agonists Price by Application (2026-2031) & (USD/Unit)

Table 40. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value by Region, (2020 VS 2024 VS 2031) & (US$ Million)

Table 41. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value by Region (2020-2025) & (US$ Million)

Table 42. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value by Region (2026-2031) & (US$ Million)

Table 43. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value by Region (2020-2025) & (%)

Table 44. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value by Region (2026-2031) & (%)

Table 45. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Volume by Region (K Units): 2020 VS 2024 VS 2031

Table 46. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Volume by Region (2020-2025) & (K Units)

Table 47. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Volume by Region (2026-2031) & (K Units)

Table 48. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Volume by Region (2020-2025) & (%)

Table 49. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Volume by Region (2026-2031) & (%)

Table 50. Global Glucagon Like Peptide-1 (GLP-1) Agonists Average Price by Region (2020-2025) & (USD/Unit)

Table 51. Global Glucagon Like Peptide-1 (GLP-1) Agonists Average Price by Region (2026-2031) & (USD/Unit)

Table 52. Key Countries/Regions Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Growth Trends, (US$ Million): 2020 VS 2024 VS 2031

Table 53. Key Countries/Regions Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value, (2020-2025) & (US$ Million)

Table 54. Key Countries/Regions Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value, (2026-2031) & (US$ Million)

Table 55. Key Countries/Regions Glucagon Like Peptide-1 (GLP-1) Agonists Sales Volume, (2020-2025) & (K Units)

Table 56. Key Countries/Regions Glucagon Like Peptide-1 (GLP-1) Agonists Sales Volume, (2026-2031) & (K Units)

Table 57. Novo Nordisk Company Information

Table 58. Novo Nordisk Introduction and Business Overview

Table 59. Novo Nordisk Glucagon Like Peptide-1 (GLP-1) Agonists Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)

Table 60. Novo Nordisk Glucagon Like Peptide-1 (GLP-1) Agonists Product Offerings

Table 61. Novo Nordisk Recent Development

Table 62. Eli Lilly Company Information

Table 63. Eli Lilly Introduction and Business Overview

Table 64. Eli Lilly Glucagon Like Peptide-1 (GLP-1) Agonists Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)

Table 65. Eli Lilly Glucagon Like Peptide-1 (GLP-1) Agonists Product Offerings

Table 66. Eli Lilly Recent Development

Table 67. AstraZeneca Company Information

Table 68. AstraZeneca Introduction and Business Overview

Table 69. AstraZeneca Glucagon Like Peptide-1 (GLP-1) Agonists Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)

Table 70. AstraZeneca Glucagon Like Peptide-1 (GLP-1) Agonists Product Offerings

Table 71. AstraZeneca Recent Development

Table 72. Sanofi Company Information

Table 73. Sanofi Introduction and Business Overview

Table 74. Sanofi Glucagon Like Peptide-1 (GLP-1) Agonists Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)

Table 75. Sanofi Glucagon Like Peptide-1 (GLP-1) Agonists Product Offerings

Table 76. Sanofi Recent Development

Table 77. GSK Company Information

Table 78. GSK Introduction and Business Overview

Table 79. GSK Glucagon Like Peptide-1 (GLP-1) Agonists Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)

Table 80. GSK Glucagon Like Peptide-1 (GLP-1) Agonists Product Offerings

Table 81. GSK Recent Development

Table 82. Hanson Company Information

Table 83. Hanson Introduction and Business Overview

Table 84. Hanson Glucagon Like Peptide-1 (GLP-1) Agonists Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)

Table 85. Hanson Glucagon Like Peptide-1 (GLP-1) Agonists Product Offerings

Table 86. Hanson Recent Development

Table 87. Shanghai Benemae Company Information

Table 88. Shanghai Benemae Introduction and Business Overview

Table 89. Shanghai Benemae Glucagon Like Peptide-1 (GLP-1) Agonists Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)

Table 90. Shanghai Benemae Glucagon Like Peptide-1 (GLP-1) Agonists Product Offerings

Table 91. Shanghai Benemae Recent Development

Table 92. Key Raw Materials Lists

Table 93. Raw Materials Key Suppliers Lists

Table 94. Glucagon Like Peptide-1 (GLP-1) Agonists Downstream Customers

Table 95. Glucagon Like Peptide-1 (GLP-1) Agonists Distributors List

Table 96. Research Programs/Design for This Report

Table 97. Key Data Information from Secondary Sources

Table 98. Key Data Information from Primary Sources

List of Figures

Figure 1. Glucagon Like Peptide-1 (GLP-1) Agonists Product Picture

Figure 2. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value, 2020 VS 2024 VS 2031 (US$ Million)

Figure 3. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value (2020-2031) & (US$ Million)

Figure 4. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Volume (2020-2031) & (K Units)

Figure 5. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Price (2020-2031) & (USD/Unit)

Figure 6. Glucagon Like Peptide-1 (GLP-1) Agonists Report Years Considered

Figure 7. Global Glucagon Like Peptide-1 (GLP-1) Agonists Players Revenue Ranking (2024) & (US$ Million)

Figure 8. Global Glucagon Like Peptide-1 (GLP-1) Agonists Players Sales Volume Ranking (2024) & (K Units)

Figure 9. The 5 and 10 Largest Manufacturers in the World: Market Share by Glucagon Like Peptide-1 (GLP-1) Agonists Revenue in 2024

Figure 10. Glucagon Like Peptide-1 (GLP-1) Agonists Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024

Figure 11. Dulaglutide Picture

Figure 12. Exenatide Picture

Figure 13. Liraglutide Picture

Figure 14. Benaglutide Picture

Figure 15. Other Picture

Figure 16. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value by Type (2020 VS 2024 VS 2031) & (US$ Million)

Figure 17. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Market Share by Type, 2024 & 2031

Figure 18. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Volume by Type (2020 VS 2024 VS 2031) & (K Units)

Figure 19. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Volume Market Share by Type, 2024 & 2031

Figure 20. Global Glucagon Like Peptide-1 (GLP-1) Agonists Price by Type (2020-2031) & (USD/Unit)

Figure 21. Product Picture of Diabetes

Figure 22. Product Picture of Obesity

Figure 23. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value by Application (2020 VS 2024 VS 2031) & (US$ Million)

Figure 24. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Market Share by Application, 2024 & 2031

Figure 25. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Volume by Application (2020 VS 2024 VS 2031) & (K Units)

Figure 26. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Volume Market Share by Application, 2024 & 2031

Figure 27. Global Glucagon Like Peptide-1 (GLP-1) Agonists Price by Application (2020-2031) & (USD/Unit)

Figure 28. North America Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value (2020-2031) & (US$ Million)

Figure 29. North America Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value by Country (%), 2024 VS 2031

Figure 30. Europe Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value, (2020-2031) & (US$ Million)

Figure 31. Europe Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value by Country (%), 2024 VS 2031

Figure 32. Asia Pacific Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value, (2020-2031) & (US$ Million)

Figure 33. Asia Pacific Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value by Region (%), 2024 VS 2031

Figure 34. South America Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value, (2020-2031) & (US$ Million)

Figure 35. South America Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value by Country (%), 2024 VS 2031

Figure 36. Middle East & Africa Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value, (2020-2031) & (US$ Million)

Figure 37. Middle East & Africa Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value by Country (%), 2024 VS 2031

Figure 38. Key Countries/Regions Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value (%), (2020-2031)

Figure 39. Key Countries/Regions Glucagon Like Peptide-1 (GLP-1) Agonists Sales Volume (%), (2020-2031)

Figure 40. United States Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value, (2020-2031) & (US$ Million)

Figure 41. United States Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value by Type (%), 2024 VS 2031

Figure 42. United States Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value by Application (%), 2024 VS 2031

Figure 43. Europe Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value, (2020-2031) & (US$ Million)

Figure 44. Europe Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value by Type (%), 2024 VS 2031

Figure 45. Europe Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value by Application (%), 2024 VS 2031

Figure 46. China Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value, (2020-2031) & (US$ Million)

Figure 47. China Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value by Type (%), 2024 VS 2031

Figure 48. China Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value by Application (%), 2024 VS 2031

Figure 49. Japan Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value, (2020-2031) & (US$ Million)

Figure 50. Japan Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value by Type (%), 2024 VS 2031

Figure 51. Japan Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value by Application (%), 2024 VS 2031

Figure 52. South Korea Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value, (2020-2031) & (US$ Million)

Figure 53. South Korea Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value by Type (%), 2024 VS 2031

Figure 54. South Korea Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value by Application (%), 2024 VS 2031

Figure 55. Southeast Asia Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value, (2020-2031) & (US$ Million)

Figure 56. Southeast Asia Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value by Type (%), 2024 VS 2031

Figure 57. Southeast Asia Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value by Application (%), 2024 VS 2031

Figure 58. India Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value, (2020-2031) & (US$ Million)

Figure 59. India Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value by Type (%), 2024 VS 2031

Figure 60. India Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value by Application (%), 2024 VS 2031

Figure 61. Glucagon Like Peptide-1 (GLP-1) Agonists Industrial Chain

Figure 62. Glucagon Like Peptide-1 (GLP-1) Agonists Manufacturing Cost Structure

Figure 63. Channels of Distribution (Direct Sales, and Distribution)

Figure 64. Bottom-up and Top-down Approaches for This Report

Figure 65. Data Triangulation

Figure 66. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$3950

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$5925

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$7900

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Global Glucagon like peptide 1 GLP 1 based Therapies Market Research Report 2025

GLP Analogs Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global GLP 1 Receptor Agonist Drugs Market Research Report 2024

Global GLP 1 Agonists for Obesity Market Research Report 2024

Global Oral GLP 1 Agonist Market Research Report 2024

Global GLP 1 Agonist Injection Market Research Report 2024

Global GLP 1 Agonists for the Treatment of both Diabetes and Obesity Market Research Report 2024

Global GLP 1 Receptor Antagonist Market Research Report 2024

GLP 1 Analogues Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global GLP 1 Drugs Market Research Report 2024

GLP 1 for Weight Loss Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global GLP 1RA Therapy Market Research Report 2024

Global GLP 1 Drug Peptide API Market Research Report 2024

Global GIP 1 Receptor Agonist Market Research Report 2024

Global GLP 1 Weight Loss Pill Market Research Report 2024

Global GLP 1 Weight Loss Drug Market Research Report 2024

Global GLP 1 Injection Market Research Report 2024

Global Liraglutide for The Treatment of Diabetes and Obesity Market Research Report 2024

Global GLP 1 Peptide Drugs Market Research Report 2024

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions